Aurobindo Pharma Ltd. — Call Transcript 2021

Feb 9, 2021

==> picture [29 x 842] intentionally omitted <==

==> picture [40 x 38] intentionally omitted <==

ToListingDepartment,NATIONALSTOCKEXCHANGEOFINDIALIMITEDExchangePlaza,BandraKurlaComplex,Bandra(E),MUMBAI-400051Company CodeNo.AUROPHARMA	ToTheCorporateRelationsDepartmentBSELIMITEDPhirozJeejeebhoyTowers,25thfloor,DalalStreet,MUMBAI-400001Company CodeNo.524804

==> picture [80 x 82] intentionally omitted <==

9[th] February 2021, Hyderabad, India

- Aurobindo Pharma Limited Q3 FY20 21 earnings call is scheduled on 11[th] February 2021 at 08:30 hrs

The dial-in details to participate in the call are as under. You may also pre-register in the call through the link mentioned below.

Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you are connected to your call in time.

Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you areconnected toyour call in time.	Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you areconnected toyour call in time.
Primary Number:	+91 22 6280 1437/+91 22 7115 8825
The number listed above are universally accessiblefrom all networks and all countries.
Local Access Number:	+91-70456 71221Available all over India
Toll Free Number:	USA: 1866 746 2133UK: 0808 101 1573Singapore: 800 101 2045HongKong: 800 964 448
Pre-register Link (URL)	https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5343979&linkSecurityString=11118a0cb2

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Krishna Kiran Investor Relations, Phone: 040-66725401 / 66725000 Mobile: +91 98486 67906 Email: ir@aurobindo.com